Janux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at Barclays

Barclays began coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a research report released on Wednesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $47.00 target price on the stock.

A number of other research analysts have also issued reports on JANX. Guggenheim started coverage on shares of Janux Therapeutics in a report on Wednesday, September 3rd. They issued a “buy” rating and a $72.00 target price on the stock. Piper Sandler began coverage on shares of Janux Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $42.00 target price on the stock. Raymond James Financial initiated coverage on shares of Janux Therapeutics in a research note on Friday, July 11th. They issued an “outperform” rating and a $65.00 target price for the company. Truist Financial initiated coverage on Janux Therapeutics in a research note on Wednesday, September 10th. They set a “buy” rating and a $100.00 price target on the stock. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $78.31.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $23.45 on Wednesday. Janux Therapeutics has a fifty-two week low of $21.97 and a fifty-two week high of $71.71. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -13.03 and a beta of 2.84. The stock’s fifty day moving average is $24.45 and its two-hundred day moving average is $26.10.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). As a group, sell-side analysts forecast that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of JANX. Osaic Holdings Inc. grew its position in Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after acquiring an additional 3,037 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Janux Therapeutics by 230.0% in the second quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock worth $4,379,000 after buying an additional 132,121 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Janux Therapeutics by 175.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock worth $91,000 after acquiring an additional 2,502 shares in the last quarter. Lazard Asset Management LLC increased its holdings in shares of Janux Therapeutics by 64.8% during the 2nd quarter. Lazard Asset Management LLC now owns 99,858 shares of the company’s stock valued at $2,306,000 after acquiring an additional 39,278 shares during the last quarter. Finally, Engineers Gate Manager LP increased its holdings in shares of Janux Therapeutics by 115.0% during the 2nd quarter. Engineers Gate Manager LP now owns 39,749 shares of the company’s stock valued at $918,000 after acquiring an additional 21,258 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.